Michał Bogacki - DOBROSTAN

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Asthma5 trials
• COPD2 trials

Phase

• Phase 25 trials
• Phase 2/31 trial
• Phase 31 trial

Status

• Completed4 trials
• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Chiesi Farmaceutici S.p.A.3 trials
• Genentech Inc.1 trial
• Kinaset Therapeutics Inc1 trial
• Pfizer1 trial
• Rapt Therapeutics Inc.1 trial

Running trials

• Recruiting

  A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

  NCT07532265· Phase 2· Kinaset Therapeutics Inc· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

  NCT07301736· Phase 2· Chiesi Farmaceutici S.p.A.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• COPD1 recruiting

Closed trials

• Completed

  Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

  NCT06264674· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy

  2022-502854-16-00· Phase 2· Rapt Therapeutics Inc.· Source

• Completed

  Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy

  2022-502208-64-00· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD)

  2023-507093-40-00· Phase 2· Genentech Inc.· Source